Topics

Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. Company Profile

03:44 EST 24th January 2020 | BioPortfolio

Ironwood Pharmaceuticals (NASDAQ: IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our team to passionately pursue excellence. We discovered, developed and are commercializing linaclotide, which is approved in the United States and a number of other countries. Our pipeline priorities include exploring further opportunities for linaclotide, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to address patient needs. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. Connect with us at www.ironwoodpharma.com or on Twitter at www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations.


News Articles [2125 Associated News Articles listed on BioPortfolio]

Alnylam, Ironwood Pharma to collaborate on givosiran promotion

A partnership has been formed between Alnylam Pharmaceuticals and Ironwood Pharmaceuticals to develop a givosiran educational -More- 

AstraZeneca revises Linzess deal with Ironwood Pharmaceuticals

AstraZeneca has revised its agreement with Ironwood Pharmaceuticals for irritable bowel syndrome with constipation (IBS-C) drug Linzess (linaclotide). Linzess is...Read More... The post AstraZeneca re...

AstraZeneca amends collaboration with Ironwood for Linzess in China

AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong and China Macau for Linzess (linaclotide), a first-in-class new tr...

Astellas Pharma files BLA for urothelial cancer candidate

A Biologics License Application was submitted by Astellas Pharma to the FDA in a bid to seek accelerated approval for its dru -More- 

Astellas Pharma to acquire Audentes Therapeutics for $3bn

Astellas Pharma has signed an agreement to acquire genetic drugs developer Audentes Therapeutics for a cash consideration of $3bn, or...Read More... The post Astellas Pharma to acquire Audentes Therap...

Astellas Pharma to buy Audentes Therapeutics for $3bn

Under the deal, Astellas US Holding wholly-owned subsidiary Asilomar Acquisition will acquire Audentes by paying $60 per share in cash. Audentes chairman and CEO Matthew Patterson said: “With The p...

Astellas Pays $3 Billion for Audentes

Japanese drugmaker Astellas Pharma has announced plans to acquire US gene therapy company Audentes Therapeutics for around $3 billion. The boards of directors of both companies have unanimously approv...

Astellas Acquires Xyphos Biosciences, Gaining Access to its ACCEL Technology Platform and Immuno-Oncology Talent

TOKYO and SOUTH SAN FRANCISCO, Calif., Dec. 26, 2019 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Xyphos Biosciences, Inc...

Drugs and Medications [75 Associated Drugs and Medications listed on BioPortfolio]

Fluoxetine hydrochloride [northwind pharmaceuticals]

NA

Fluoride [mayne pharma inc]

Fluoride Chewable Tablets 0.5 mg

Fluoride [mayne pharma inc]

Fluoride Chewable Tablets 1 mg

Valsartan and hydrochlorothiazide [northwind pharmaceuticals]

NA

Urea [mayne pharma inc.]

Rx Only 45% Urea Nail Gel In a vehicle containing Camphor, Eucalyptus Oil and Menthol )

PubMed Articles [144 Associated PubMed Articles listed on BioPortfolio]

Data science tools and applications on the way to Pharma 4.0.

Multiple obstacles are driving the digital transformation of the biopharmaceutical industry. Novel digital techniques, often marketed as 'Pharma 4.0', are thought to solve some long-existing obstacles...

Mytilidae as model organisms in the marine ecotoxicology of pharmaceuticals - A review.

Growing production and consumption of pharmaceuticals is a global problem. Due to insufficient data on the concentration and distribution of pharmaceuticals in the marine environment, there are no app...

III. THE ROLE OF THE RESEARCH ETHICS COMMITTEES IN THE REGULATION OF PHARMA-SPONSORED STUDIES.

Participants of Pharma-sponsored research are exposed to risks, benefits, and uncertainties that do not occur in other forms of clinical studies. Ethics committees represent the subjects' first line o...

Occurrence and ranking of pharmaceuticals in the major rivers of China.

Residual pharmaceuticals have received widespread attention worldwide due to their continuous release and potential hazard to the environment. As a result of rapid development and a large population, ...

Analysis, occurrence and removal of pharmaceuticals in African water resources: A current status.

Pharmaceuticals are organic compounds used in medicines for alleviation of pain. Since 2017, there has been a steady increase on the availability of information on contamination of water resources cau...

Clinical Trials [344 Associated Clinical Trials listed on BioPortfolio]

A Bioequivalence Study of Dexlansoprazole From Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant 60 mg Delayed Release (DR) Capsules (Takeda Pharmaceuticals America Inc., USA)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Dexlansoprazole from Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant...

To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)

This is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Tacrolimus Ointment, 0.1% (Glenmark Pharmac...

Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition

The primary objective is to determine clinical bioequivalence of Amphotericin B liposome for injection of Auromedics Pharma LLC, USA and AmBisome (Amphotericin B) liposome for injection of...

Bioequivalence Study of Tacrolimus 5 mg Capsule Under Fed Condition

The objective of the study is to demonstrate bioequivalence between Test Product (A): Tacrolimus Capsules 5 mg, manufactured by Panacea Biotec Limited, India and the corresponding Referenc...

Bioequivalence Study of Tacrolimus 1 mg Capsule Under Fed Condition

The objective of the study is to demonstrate bioequivalence between Test Product (A): Tacrolimus Capsules 1 mg, manufactured by Panacea Biotec Limited, India and the corresponding Referenc...

Companies [2226 Associated Companies listed on BioPortfolio]

Astellas Pharma Canada, Inc.

Astellas Pharma Europe Ltd., located in the UK, is the European Headquarters of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the he...

Astellas Pharma Inc.

Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals...

Astellas Pharma Global Development

Astellas Pharma Global Development, located in Deerfield, Illinois, is a group company of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of peo...

Almirall, S.A. and Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood's GC-C agon...

Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc.

Ironwood Pharmaceuticals (NASDAQ: IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholde...

More Information about "Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc." on BioPortfolio

We have published hundreds of Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. news stories on BioPortfolio along with dozens of Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. Clinical Trials and PubMed Articles about Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. Companies in our database. You can also find out about relevant Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks



Searches Linking to this Company Record